Genmab is building a deep pipeline of fully human antibody products to maximize its opportunities for success. We have seven products in clinical trials and have the financial flexibility needed to move our products forward. Genmab has chosen to focus on products to treat various cancers, where human antibodies are expected to be particularly useful as they should lend themselves to long-term therapy without the risk of rejection by the body's immune system. Furthermore, Genmab is evaluating a large number of interesting disease targets for future product development.